Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
Inspire Medical Systems Inc ownership report: Vanguard Capital Management reported beneficial ownership of 1,469,703 shares of Common Stock, representing 5.10% of the class. The filing shows sole voting power for 202,965 shares and sole dispositive power for 1,469,703 shares. The statement clarifies these holdings reflect securities managed by Vanguard Capital Management LLC and specified affiliates.
Inspire Medical Systems ownership filing: Vanguard Portfolio Management reports beneficial ownership of 1,644,767 shares of Common Stock, representing 5.71% of the class. The filer states sole dispositive power over 1,644,767 shares and sole voting power for 7,594 shares. The disclosure notes holdings include Vanguard funds and managed accounts over which Vanguard exercises dispositive power.
Broader Shelley G reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems director Shelley G. Broader received 342 shares of Common Stock as a stock grant. The shares were valued at $52.07 per share and were issued in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. Following this routine compensation award, Broader directly holds a total of 4,909 shares of Inspire Medical Systems Common Stock.
Inspire Medical Systems, Inc. director Georgia Melenikiotou received 307 shares of common stock as a grant classified as a “grant, award, or other acquisition.” These shares were issued at $52.07 per share in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, bringing her direct holdings to 4,473 shares.
Ellis Gary Lee reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems director Ellis Gary Lee received 518 shares of Common Stock as a stock award. The shares were granted at a value of $52.07 per share and were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. Following this award, Lee directly holds 7,276 shares of Inspire Medical Systems common stock.
Tansey Casey M reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems director Casey M. Tansey received a grant of 308 shares of Common Stock on April 15, 2026, as stock compensation in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reference price of $52.07 per share.
Following this award, Tansey directly holds 22,724 shares. Additional shares are reported as held indirectly through two family irrevocable trusts, each holding 500 shares of Common Stock.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting its relationship to Inspire Medical Systems common stock. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report separately under SEC Release No. 34-39538. The filing discloses amount beneficially owned: 0 and percent of class: 0%.
Inspire Medical Systems is asking shareholders to vote at a fully virtual annual meeting on April 30, 2026. The proxy seeks approval to re-elect three Class II directors, ratify Ernst & Young as auditor for 2026, and hold advisory votes on executive pay and how often that say‑on‑pay vote should occur.
Shareholders are also asked to approve declassifying the board so all directors stand for annual election starting with the 2029 meeting, amend and restate the 2018 Incentive Award Plan to support broad-based equity compensation, and allow adjournment if more time is needed to pass these items. The proxy highlights 2025 revenue of $912 million, up 14% over 2024, adjusted net income of $72.1 million, adjusted diluted EPS of $2.42, and strong margins as Inspire scales its sleep apnea therapy business.